Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (5657)	9/24/1998 8:25:00 AM
From: Craig Markell	Respond to of 7041

Zonagen Earns $5 Million Milestone for Vasomax THE WOODLANDS, Texas--(BW HealthWire)--Sept. 24, 1998--Zonagen Inc. (Nasdaq:ZONA - news; PCX:ZNG) today announced that the company has earned a milestone payment of $5 million from Schering-Plough Corporation (NYSE:SGP - news), the company's licensing partner for Vasomax(R). Under the terms of the license agreement this milestone was payable to Zonagen upon FDA acceptance for filing of the New Drug Application (NDA) for Vasomax(R). Vasomax(R), Zonagen's rapidly-disintegrating oral formulation of phentolamine mesylate, was licensed worldwide to Schering-Plough Corporation on November 17, 1997 for the treatment of male erectile dysfunction. Zonagen Inc. specializes in products and services for management of reproductive health. Its technologies focus on the areas of urology, female health and contraception. Through its wholly owned subsidiary, Fertility Technologies Inc. (FTI), Zonagen sells devices, instruments and supplies to the fertility specialist and the OB/GYN. A copy of this press release may be obtained via facsimile by dialing 1-888-329-0920 or via the Internet by accessing www.zonagen.com. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including but not limited to those relating to the Company's early stage of development, clinical trial results and FDA approval, substantial dependence on one product, history of operating losses, future capital needs and additional funding, ability to protect patents and proprietary technology, litigation, governmental regulation, limited sales and marketing experience and dependence on collaborators, limited manufacturing capabilities and reliance on third-party manufacturers, competition and technological change, product liability and insurance, and other risks identified in the Company's Annual Report on Form 10-K for the year ended December 31, 1997, as filed with the Securities and Exchange Commission.